Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin
- PMID: 16854067
- DOI: 10.1021/jm0603419
Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin
Abstract
Tryptophans at positions 4 and 7 of compstatin, a peptide complement inhibitor, are crucial for its interaction with C3. However, the nature of their involvement has not been studied to date. Here we investigate the molecular forces involved in the C3-compstatin interactions, mediated by aromatic residues, by incorporating in these two positions various tryptophan analogues (5-methyltryptophan, 5-fluorotryptophan, 1-methyltryptophan, and 2-naphthylalanine) and assessing the resulting peptides for activity by enzyme-linked immunosorbent assay (ELISA) and binding by isothermal titration calorimetry (ITC). Of all the compstatin analogues, peptides containing 1-methyltryptophan at position 4 exhibited the highest binding affinity (Kd = 15 nM) and activity (IC50 = 0.205 microM), followed by a peptide containing 5-fluorotryptophan at position 7. Our observations suggest that hydrophobic interactions involving residues at position 4 and the hydrogen bond initiated by the indole nitrogen are primarily responsible and crucial for the increase in activity. These findings have important implications for the design of clinically useful complement inhibitors.
Similar articles
-
Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin.J Biol Chem. 2004 Dec 31;279(53):54987-95. doi: 10.1074/jbc.M409963200. Epub 2004 Oct 15. J Biol Chem. 2004. PMID: 15489226
-
Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin.J Mol Recognit. 2009 Nov-Dec;22(6):495-505. doi: 10.1002/jmr.972. J Mol Recognit. 2009. PMID: 19658192 Free PMC article.
-
A new generation of potent complement inhibitors of the Compstatin family.Chem Biol Drug Des. 2011 Jun;77(6):431-40. doi: 10.1111/j.1747-0285.2011.01111.x. Epub 2011 Apr 26. Chem Biol Drug Des. 2011. PMID: 21352502 Free PMC article.
-
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.Eur J Clin Invest. 2015 Apr;45(4):423-40. doi: 10.1111/eci.12419. Epub 2015 Mar 9. Eur J Clin Invest. 2015. PMID: 25678219 Free PMC article. Review.
-
Compstatin: a complement inhibitor on its way to clinical application.Adv Exp Med Biol. 2008;632:273-92. doi: 10.1007/978-0-387-78952-1_20. Adv Exp Med Biol. 2008. PMID: 19025129 Free PMC article. Review.
Cited by
-
Complement regulation in the eye: implications for age-related macular degeneration.J Clin Invest. 2024 May 1;134(9):e178296. doi: 10.1172/JCI178296. J Clin Invest. 2024. PMID: 38690727 Free PMC article. Review.
-
A guide to complement biology, pathology and therapeutic opportunity.Nat Rev Immunol. 2024 Feb;24(2):118-141. doi: 10.1038/s41577-023-00926-1. Epub 2023 Sep 5. Nat Rev Immunol. 2024. PMID: 37670180 Review.
-
Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors.Nat Commun. 2022 Sep 20;13(1):5519. doi: 10.1038/s41467-022-33003-7. Nat Commun. 2022. PMID: 36127336 Free PMC article.
-
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.Ther Adv Hematol. 2022 Jul 28;13:20406207221114673. doi: 10.1177/20406207221114673. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35923770 Free PMC article. Review.
-
Deciphering the conformational landscape of few selected aromatic noncoded amino acids (NCAAs) for applications in rational design of peptide therapeutics.Amino Acids. 2022 Aug;54(8):1183-1202. doi: 10.1007/s00726-022-03175-z. Epub 2022 Jun 20. Amino Acids. 2022. PMID: 35723743 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous